List of Vimovo drug patents

Vimovo is owned by Horizon.

Vimovo contains Esomeprazole Magnesium; Naproxen.

Vimovo has a total of 9 drug patents out of which 6 drug patents have expired.

Expired drug patents of Vimovo are:

  • US8858996
  • US8852636
  • US9161920
  • US9198888
  • US9707181
  • US9345695

Vimovo was authorised for market use on 30 April, 2010.

Vimovo is available in tablet, delayed release;oral dosage forms.

Vimovo can be used as risk-reduction of nsaid-associated gastric ulcers in patients also taking low dose aspirin, risk-reduction of nsaid-associated gastric ulcer in patients requiring nsaid treatment, relief of signs and symptoms of arthritis and risk-reduction of nsaid-associated gastric ulcer, risk-reduction of nsaid gastric ulcer in patients requiring chronic nsaid treatment.

The generics of Vimovo are possible to be released after 17 October, 2031.

VIMOVO's oppositions filed in EPO
VIMOVO Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8858996 HORIZON Pharmaceutical compositions for the coordinated delivery of NSAIDS
May, 2022

(9 months ago)

US8852636 HORIZON Pharmaceutical compositions for the coordinated delivery of NSAIDs
May, 2022

(9 months ago)

US9161920 HORIZON Pharmaceutical compositions for the coordinated delivery of NSAIDs
May, 2022

(9 months ago)

US9198888 HORIZON Pharmaceutical compositions for the coordinated delivery of NSAIDs
May, 2022

(9 months ago)

US9707181 HORIZON Pharmaceutical compositions for the coordinated delivery of NSAIDs
May, 2022

(9 months ago)

US9345695 HORIZON Pharmaceutical compositions for the coordinated delivery of NSAIDs
May, 2022

(9 months ago)

US9393208 HORIZON Method for delivering a pharmaceutical composition to patient in need thereof
Sep, 2029

(6 years from now)

US9220698 HORIZON Method for delivering a pharmaceutical composition to patient in need thereof
Mar, 2031

(7 years from now)

US8945621 HORIZON Method for treating a patient at risk for developing an NSAID-associated ulcer
Oct, 2031

(8 years from now)

Drugs and Companies using ESOMEPRAZOLE MAGNESIUM; NAPROXEN ingredient

Market Authorisation Date: 30 April, 2010

Treatment: Relief of signs and symptoms of arthritis and risk-reduction of nsaid-associated gastric ulcer; Risk-reduction of nsaid gastric ulcer in patients requiring chronic nsaid treatment; Risk-reduction of n...

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of VIMOVO before it's patent expiration?
More Information on Dosage

VIMOVO family patents

26

United States

5

Australia

5

European Union

3

Mexico

3

Japan

EA

3

EA

3

Canada

2

Morocco

2

Norway

2

Brazil

2

Korea, Republic of

2

China

2

Tunisia

1

Israel

1

South Africa

1

Denmark

1

Austria

1

Belgium

1

Germany

1

Singapore

1

Sweden

1

Portugal

1

Cyprus

1

Spain

1

United Kingdom

1

Luxembourg

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic